In 2006, GeneChem raised its third focused fund to capitalise on the growth of the aging "Baby Boomer" segment of the population. With committed capital of $65M, the AgeChem Venture Fund L.P. sought to invest in companies developing therapeutics targeting diseases affecting the aging population, such as metabolic disorders (e.g. diabetes, obesity), cardiovascular diseases, cancers, diseases of the central nervous system (e.g. Alzheimer, Parkinson, insomnia), inflammatory diseases (e.g. rheumatoid arthritis, psoriasis) etc.

This fund is no longer seeking new investments.